Company / SG&A Expense
NewAmsterdam Pharma Co N.V. SG&A Expense History
FY2021-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest SG&A Expense
$106.4M
FY2025
5-year range
$6.0M / $106.4M
FY2021-FY2025
Trend
+51.0%
vs FY2024
Sector context
#109 of 212
Health Care
What the data says
At $106M, NewAmsterdam Pharma Co N.V.'s sg&a expense ranks #104 of 212 in the Health Care sector. SG&A Expense has increased for 4 consecutive years, from $6M in FY2021 to $106M in FY2025.
Based on SEC 10-K filings.
$106M in FY2025 with a 3-year CAGR of +76.0%.
Increased from $38M to $106M over the past 2 years.
Health Care sector context is included.
SG&A Expense over time
Growth rates
- 3-Year CAGR
- +76.0%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#104 of 212 in Health CareTop 49% of 212This company $106.4M Sector average $722.9M
▼
-85.3% below sector average
Key checks
Key Insights
- NewAmsterdam Pharma Co N.V.'s sg&a expense has grown for 4 consecutive years.
- 3-year CAGR of +76.0%, indicating consistent growth.
- In FY2025, sg&a expense increased 51.0% year-over-year.
- Ranks #109 out of 212 companies in the Health Care sector.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score 3.01 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | SG&A ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $106.4M | +51.0% |
| FY2024 | $70.4M | +87.2% |
| FY2023 | $37.6M | +92.9% |
| FY2022 | $19.5M | +225.0% |
| FY2021 | $6.0M | - |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026